CVS Health Corp (CVS) Position Lifted by Gillespie Robinson & Grimm Inc.

Gillespie Robinson & Grimm Inc. boosted its holdings in shares of CVS Health Corp (NYSE:CVS) by 2.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 303,406 shares of the pharmacy operator’s stock after purchasing an additional 7,413 shares during the period. CVS Health makes up 2.8% of Gillespie Robinson & Grimm Inc.’s investment portfolio, making the stock its 23rd largest holding. Gillespie Robinson & Grimm Inc.’s holdings in CVS Health were worth $21,997,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of CVS. Fieldpoint Private Securities LLC lifted its stake in shares of CVS Health by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 1,000 shares during the period. Wealthcare Advisory Partners LLC lifted its stake in shares of CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 991 shares during the period. Arcadia Investment Management Corp MI lifted its stake in shares of CVS Health by 119.6% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after acquiring an additional 726 shares during the period. MPS Loria Financial Planners LLC acquired a new stake in shares of CVS Health in the 2nd quarter worth $119,000. Finally, Captrust Financial Advisors acquired a new stake in shares of CVS Health in the 2nd quarter worth $155,000. 80.81% of the stock is currently owned by institutional investors.

Shares of CVS Health Corp (CVS) opened at $71.90 on Friday. The company has a quick ratio of 0.52, a current ratio of 1.02 and a debt-to-equity ratio of 0.59. CVS Health Corp has a 52 week low of $66.45 and a 52 week high of $84.00. The company has a market cap of $72,830.00, a PE ratio of 11.11, a P/E/G ratio of 1.20 and a beta of 0.92.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.88 by $0.04. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The firm had revenue of $48.39 billion during the quarter, compared to analysts’ expectations of $47.54 billion. During the same quarter last year, the business earned $1.71 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. research analysts forecast that CVS Health Corp will post 6.38 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, February 2nd. Shareholders of record on Wednesday, January 24th were given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 2.78%. The ex-dividend date of this dividend was Tuesday, January 23rd. CVS Health’s payout ratio is currently 30.91%.

Several analysts have recently commented on CVS shares. Robert W. Baird restated a “hold” rating and issued a $77.00 target price on shares of CVS Health in a research note on Friday, October 27th. Needham & Company LLC upgraded shares of CVS Health from a “hold” rating to a “buy” rating and raised their target price for the stock from $69.02 to $79.00 in a research note on Friday, November 10th. Deutsche Bank restated a “hold” rating on shares of CVS Health in a research note on Tuesday, December 5th. Mizuho set a $90.00 target price on shares of CVS Health and gave the stock a “buy” rating in a research note on Tuesday, October 24th. Finally, Raymond James Financial restated a “buy” rating on shares of CVS Health in a research note on Monday, December 4th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. CVS Health currently has an average rating of “Buy” and an average target price of $87.82.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of CVS Health stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the transaction, the executive vice president now owns 15,556 shares in the company, valued at $1,166,700. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.61% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “CVS Health Corp (CVS) Position Lifted by Gillespie Robinson & Grimm Inc.” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/17/cvs-health-corp-cvs-position-lifted-by-gillespie-robinson-grimm-inc.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply